Pharming Group NV - Company Profile
Powered by 
All the sales intelligence you need on Pharming Group NV in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Pharming Group NV fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Pharming Group NV.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Pharming Group NV (Pharming) is a biopharmaceutical company specialized in the development and commercialization of innovative protein replacement therapies and precision medicines for rare diseases. The company's major products include Ruconest, a recombinant C1 inhibitor protein replacement therapy for hereditary angioedema (HAE), and Joenja, a small molecule kinase inhibitor for activated PI3K delta syndrome (APDS). Patients with rare, debilitating, and life-threatening diseases primarily use Pharming's products. The company collaborates with partners such as Sanofi and BioConnection for manufacturing and supply processes. It has operations in the US, France, and the Netherlands. Pharming is headquartered in Leiden, Zuid-Holland, The Netherlands.
Headquarters
Netherlands
Address
Darwinweg 24, Leiden, Zuid-Holland, 2333CR
Website
www.pharming.com
Telephone
31 715 247400
No of Employees
407
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHARM (AMS)
Revenue (2024)
$376.1M
26.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
124.1%
(2024 vs 2023)
Market Cap*
$967.1M
Net Profit Margin (2024)
XYZ
119.1%
(2024 vs 2023)
* As of and is in US$
Pharming Group NV premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Recombinant C1 esterase inhibitor, or rhC1INH, protein replacement therapy: To treat acute attacks with hereditary angioedema. | Joenja |
| Leniolisib: To treat activated phosphoinositide 3-kinase delta, or PI3Kδ, syndrome, or APDS, a primary immunodeficiency, or PID, in adult and pediatric patients 12 years of age and older. | Ruconest |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In December, the company acquired Abliva AB. |
| 2025 | Regulatory Approval | In January, Pharming Technologies secured the necessary regulatory approval for the recommended cash offer to the shareholders of Abliva AB. |
| 2024 | Regulatory Approval | In September, the company received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Joenja (leniolisib) to treat activated phosphoinositide 3-kinase delta syndrome in adult and pediatric patients 12 years of age and older. |
Competitor Comparison
| Key Parameters | Pharming Group NV | Takeda Pharmaceutical Co Ltd | Argenx SE | BioMarin Pharmaceutical Inc | Ionis Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | Netherlands | Japan | Netherlands | United States of America | United States of America |
| City | Leiden | Chuo-Ku | Amsterdam | San Rafael | Carlsbad |
| State/Province | Zuid-Holland | Tokyo | Noord-Holland | California | California |
| No. of Employees | 407 | 47,029 | 1,863 | 3,221 | 1,402 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Fabrice Chouraqui | Director; Chief Executive Officer | Executive Board | 2025 | - |
| Kenneth Lynard | Chief Financial Officer | Senior Management | 2025 | - |
| Mireille Sanders | Chief Operating Officer | Senior Management | 2020 | 56 |
| Ines Bernal | Chief People Officer | Senior Management | 2024 | 47 |
| Anurag Relan, MD | Chief Medical Officer | Senior Management | 2021 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer